What is
Myasthenia Gravis?
Myasthenia gravis (MG) is a chronic autoimmune neuromuscular disease characterised by fluctuating skeletal muscle weakness that worsens with activity and improves with rest. The name derives from the Latin and Greek for "grave muscular weakness" — a description that, while accurate in severe cases, no longer reflects the prognosis achievable with modern management and holistic support.[1]
MG is the most common primary disorder of the neuromuscular junction and affects an estimated 14 to 20 people per 100,000 — a figure that has been rising globally, in part due to improved diagnosis. It can affect individuals at any age, though there is a bimodal distribution: a younger female-predominant peak before age 40 and an older male-predominant peak after age 60.[2]
The essential feature of MG is impaired neuromuscular transmission — the process by which the nervous system commands a muscle to contract. In a healthy neuromuscular junction, acetylcholine (ACh) released from a motor nerve terminal crosses the synaptic cleft and binds to acetylcholine receptors (AChR) on the muscle surface, triggering contraction. In MG, this process is disrupted by autoantibodies that attack these receptors and the structures that support them.
In plain language: Your immune system is producing antibodies that interfere with the way your muscles receive signals from your nervous system. This makes your muscles tire unusually quickly, particularly with repeated use. The weakness is real, measurable, and has a clear biological cause. It is not anxiety, deconditioning, or a functional disorder.
The Underlying
Mechanism
In approximately 85% of MG cases, pathogenic autoantibodies target the nicotinic acetylcholine receptor (nAChR) at the postsynaptic membrane of the neuromuscular junction. These anti-AChR antibodies impair neuromuscular transmission through three distinct mechanisms.[3]
In approximately 6–8% of generalised MG cases, antibodies target muscle-specific receptor tyrosine kinase (MuSK), a protein essential for the formation and maintenance of the neuromuscular junction. MuSK-MG differs clinically from AChR-MG, typically presenting with prominent bulbar, facial, and respiratory weakness, and responds differently to treatment. A smaller subset carries anti-LRP4 antibodies.[5]
The role of the thymus is central to MG pathogenesis. The thymus is a primary lymphoid organ responsible for T cell maturation and immune tolerance. In MG, thymic abnormalities — hyperplasia in the majority and thymoma in approximately 10–15% of patients — are thought to drive the autoimmune response by presenting AChR-like epitopes to autoreactive T cells, which in turn support the B cell production of pathogenic antibodies.[6]
The safety margin of the neuromuscular junction. The healthy neuromuscular junction has a considerable safety margin — far more ACh is released and far more AChRs are present than are actually required for reliable contraction. In MG, this safety margin is progressively eroded by antibody-driven receptor loss and structural damage. Symptoms emerge only once the safety margin is sufficiently depleted — which explains why MG is often initially missed and why symptoms can fluctuate dramatically with activity, illness, temperature, and emotional stress.
Your immune system has made a targeting error. It is producing antibodies that attack the receiving stations at your muscle junctions — either blocking chemical signals from arriving, reducing the number of receiving stations available, or physically damaging the structure of the junction itself. Your muscles are not diseased. They are receiving insufficient instruction. The goal of holistic support is to reduce the immune system's misdirected activity and protect the biological systems that regulate it.
Clinical Subtypes and
Areas of Involvement
Ocular Myasthenia Gravis (OMG)
In approximately 50% of MG patients, the first symptoms involve the extraocular muscles — those controlling eye movement and eyelid position. Ocular MG presents as ptosis (drooping of the upper eyelid, often asymmetric or alternating) and diplopia (double vision) caused by weakness of the muscles responsible for conjugate gaze. Approximately 50–60% of patients presenting with ocular MG will generalise to involve other muscle groups within two to three years, though some patients remain purely ocular throughout their disease course.[7]
Generalised Myasthenia Gravis
When MG extends beyond the extraocular muscles, it is classified as generalised. Weakness in generalised MG characteristically involves the proximal limb muscles (arms more than legs), neck extensors, and respiratory musculature. The pattern is fatigable — strength may appear near-normal at rest but deteriorates predictably with repeated or sustained use.[1]
Bulbar Involvement and the Brainstem Region
Bulbar MG involves the muscles innervated by cranial nerves arising from the brainstem — those governing swallowing, chewing, speech, and facial expression. Weakness of the palate, pharynx, and larynx produces dysarthria (slurred, nasal speech), dysphagia (difficulty swallowing), and nasal regurgitation of liquids. Jaw fatigue during chewing and facial muscle weakness causing the characteristic "snarling smile" are also seen.
The brainstem nuclei that govern these functions — the nucleus ambiguus, the dorsal vagal nucleus, the facial nucleus, and the trigeminal motor nucleus — are not themselves diseased in MG. Rather, it is the neuromuscular junctions of the muscles they innervate that are impaired. However, bulbar involvement represents a significant escalation in disease severity and substantially increases the risk of myasthenic crisis.[8]
Respiratory Involvement and Myasthenic Crisis
The most life-threatening manifestation of MG is respiratory muscle weakness — diaphragmatic and intercostal muscle failure leading to ventilatory compromise. Myasthenic crisis is defined as MG-related respiratory failure sufficient to require intubation and mechanical ventilation, or the imminent threat of such failure.[9]
Myasthenic crisis occurs in 15–20% of MG patients at some point in their disease course and carries a mortality rate of approximately 4–8% in the modern era — historically far higher. Crises are most frequently precipitated by respiratory infections, but may also be triggered by surgical procedures, certain medications (including aminoglycosides, fluoroquinolones, beta-blockers, and magnesium), emotional stress, heat exposure, pregnancy, and abrupt withdrawal of immunosuppressive therapy.[10]
Causes and
Risk Factors
MG is a multifactorial disease in which genetic susceptibility intersects with environmental and immunological triggers. It is not directly inherited — having a family member with MG modestly increases risk but the disease does not follow Mendelian inheritance patterns. The underlying loss of immune tolerance to AChR and related proteins is the central pathological event, but the precise triggers that break tolerance in any given individual are incompletely understood.[5]
Prognosis and
Disease Course
The natural history of MG has been substantially altered by the availability of immunosuppressive therapy, plasmapheresis, intravenous immunoglobulin, and — more recently — complement inhibitors and FcRn-blocking therapies. The majority of patients achieve good functional status with appropriate treatment. However, MG is a chronic disease requiring long-term management, and the concept of remission in MG — complete stable remission (CSR), defined as the absence of symptoms without medications for at least one year — is achieved by only a minority.[11]
Most people with MG live active, productive lives with appropriate management. The disease does not directly affect intellect, sensation, autonomic function, or lifespan in the majority of cases. The key risks — myasthenic crisis and the side effects of long-term immunosuppression — can be significantly mitigated by careful monitoring, informed self-management, and a proactive approach to reducing the underlying immune dysregulation driving the disease. That is precisely the focus of the Bonner Natural Health protocol.
The Endocannabinoid System —
Your Body's Master Regulator
The endocannabinoid system (ECS) is one of the most extensive and functionally important regulatory networks in the human body. Its receptors — CB1 and CB2 — are distributed throughout the central nervous system, peripheral nervous system, immune tissues, gut, reproductive organs, skin, and skeletal muscle. Its primary function is homeostasis: the continuous, dynamic work of maintaining biological balance across multiple physiological systems simultaneously.
The ECS was not discovered until 1988 (CB1) and 1993 (CB2), making it one of the most recently identified major receptor systems in human biology. This late discovery explains why it is absent from most medical school curricula and why the majority of physicians remain largely unaware of its significance. Yet its role in regulating immune function, neurological signalling, inflammation, pain, sleep, mood, and energy metabolism is now extensively documented in peer-reviewed literature.[14]
CB1 Receptors — Neurological Regulation
CB1 receptors are the most abundant G-protein coupled receptors in the brain. They are found at presynaptic terminals of both GABAergic and glutamatergic neurons, where they regulate neurotransmitter release through retrograde signalling. When a postsynaptic neuron is depolarised, it synthesises endocannabinoids — primarily 2-arachidonoylglycerol (2-AG) and anandamide (AEA) — which travel backwards across the synapse to activate CB1 receptors at the presynaptic terminal, modulating the release of excitatory or inhibitory neurotransmitters. This retrograde signalling mechanism is fundamental to synaptic plasticity, neuroprotection, and the regulation of neuronal excitability.[15]
CB2 Receptors — Immune Regulation
CB2 receptors are expressed predominantly in immune cells and tissues — B lymphocytes, natural killer cells, monocytes, neutrophils, and T cells — with expression levels that vary by cell type and activation state. CB2 is also expressed in the thymus, spleen, tonsils, and bone marrow. Activation of CB2 receptors modulates cytokine production, suppresses pro-inflammatory signalling cascades, reduces T cell proliferation, and promotes immune tolerance.[16]
Critically for autoimmune disease, CB2 activation consistently reduces the production of inflammatory cytokines including IL-1β, IL-8, IL-12, TNF-α, and IFN-γ, while promoting regulatory T cell (Treg) function — the very cells whose role is to prevent the immune system from attacking self-tissue. CB2 receptor expression is significantly upregulated in activated immune cells and inflamed tissues, suggesting the ECS is attempting to mount an endogenous regulatory response to immunological disruption.[16]
MG is, at its core, a disease of immune dysregulation. The ECS is the body's primary endogenous immune regulatory system.
The connection is not incidental. The same CB2 receptors that modulate T cell and B cell activity, suppress complement activation, reduce pro-inflammatory cytokine release, and promote immune tolerance are the receptors most directly involved in the autoimmune cascade that drives MG. Supporting ECS function — through broad-spectrum phytocannabinoid supplementation delivered at therapeutic bioavailability — is not a symptomatic intervention. It is a systems-level approach targeting the underlying immunological mechanism of the disease.
The ECS in Myasthenia Gravis —
Specific Mechanisms
The relevance of the ECS to MG extends across multiple overlapping mechanisms. Research directly linking cannabinoids to MG remains an emerging field — MG is a rare disease and formal clinical trials of cannabinoid therapy in MG have not yet been conducted. However, the preclinical evidence, combined with the well-established ECS role in autoimmune neurological disease more broadly, provides a compelling scientific basis for ECS-based support in MG.[17]
Direct Neuromuscular Junction Evidence
In 2018, Morsch et al. demonstrated for the first time in a mouse model of MuSK-positive MG — generated using IgG from anti-MuSK-positive patients — that the cannabinoid agonist WIN 55,212-2 acutely rescued disease-impaired neuromuscular transmission. The mechanism involved cannabinoid receptor-mediated modulation of calcium release from the sarcoplasmic reticulum and acetylcholinesterase (AChE) inhibition at the junction.[17]
Additionally, research from Puopolo et al. found that multiple phytocannabinoids — including CBD, CBG, CBGA, CBN, and CBDV — demonstrate moderate inhibitory effects on acetylcholinesterase (AChE) and butyrylcholinesterase (BChE), the enzymes responsible for degrading acetylcholine in the synaptic cleft. By slowing ACh degradation, these cannabinoids act through a mechanism analogous — though distinct in mechanism — to the acetylcholinesterase inhibitors (pyridostigmine) used as first-line pharmacological management in MG.[17]
Clinical significance: The acetylcholinesterase inhibitory activity of multiple phytocannabinoids provides a biologically plausible mechanism by which broad-spectrum cannabinoid supplementation could directly support neuromuscular transmission in MG, over and above the immunomodulatory effects operating at the CB2 receptor level.
Immunomodulation — CB2 and the Autoimmune Cascade
The autoimmune machinery driving MG — T cell-dependent B cell activation, complement cascade engagement, thymic dysregulation, and inflammatory cytokine production — is substantially regulated by CB2 receptor signalling. CB2 is expressed at particularly high levels in B lymphocytes (the cells producing anti-AChR antibodies), natural killer cells, monocytes, and dendritic cells. CB2 agonism suppresses B cell proliferation and reduces pathogenic IgG production, directly relevant to the antibody-driven pathology of MG.[16]
The complement system plays a critical effector role in MG — anti-AChR antibodies activate complement at the neuromuscular junction, generating membrane attack complexes that destroy postsynaptic architecture. ECS activation has been shown to attenuate complement-mediated damage and reduce microglial and macrophage activation, providing a secondary layer of neuroprotective and junction-protective benefit.[14]
Neuroinflammation and the Gut-Brain-Immune Axis
MG is increasingly understood as a systemic disease with gut microbiome involvement. ECS receptors are densely distributed throughout the gastrointestinal tract, where they regulate intestinal barrier integrity, mucosal immune responses, and the bidirectional gut-brain axis. Broad-spectrum phytocannabinoid support directly addresses gut-immune axis dysregulation — a foundational component of autoimmune pathogenesis that conventional MG management does not address.[15]
The Bonner Natural Health
Delivery Protocol
The Bonner Natural Health chronic disease protocol uses a multi-route delivery system for broad-spectrum phytocannabinoid support. Each delivery route serves a distinct pharmacokinetic purpose — together they create systemic ECS activation, targeted regional support, and rapid bioavailability that no single delivery route can achieve alone. The formulations used in the BNH chronic disease protocol are higher-potency than those used in the standard Sovereign ECS women's wellness line, reflecting the more intensive ECS support required in chronic and autoimmune disease.
Why three routes? Each delivery method activates the ECS through a different pharmacokinetic profile: suppositories provide high-bioavailability sustained systemic activation; topicals provide targeted regional CB receptor engagement without systemic load; sublingual provides rapid flexible dosing. Used together, the three routes provide continuous, layered ECS support — maintaining endocannabinoid tone throughout the day rather than relying on intermittent peaks from a single delivery format.
Nutritional Foundation —
Seyfried and Gundry Principles
Nutrition is a tertiary but meaningful component of the Bonner Natural Health approach to MG — it does not replace ECS support or conventional management, but it addresses the metabolic and inflammatory environment in which the immune system operates. Two bodies of work are most relevant: the metabolic and mitochondrial framework of Professor Thomas Seyfried of Boston College, and the lectin-reduction and gut-integrity model of Dr. Steven Gundry.
The Seyfried Metabolic Framework Applied to MG
Professor Seyfried's central thesis is that dysfunctional mitochondria and the shift from oxidative phosphorylation to fermentative metabolism (glucose and glutamine fermentation) is a foundational driver of chronic disease — not exclusively cancer, but any pathological state characterised by mitochondrial compromise and disordered cellular energy production.[18]
In the context of MG and autoimmune disease, the relevance is significant: autoimmune effector cells — the T cells and B cells driving the anti-AChR response — are metabolically highly active, relying heavily on aerobic glycolysis (the Warburg effect) and glutamine metabolism to fuel their proliferation and antibody production. Restricting fermentable fuels through a ketogenic, low-carbohydrate dietary strategy reduces the metabolic substrate available to these hyperactive immune cells while maintaining or improving the oxidative phosphorylation capacity of healthy regulatory cells, including T regulatory cells (Tregs).[19]
The principle in practice: A therapeutic ketogenic diet — high fat, very low carbohydrate, moderate protein, with restriction of glutamine-rich foods — shifts cellular energy metabolism away from glucose fermentation. This metabolic shift preferentially disadvantages hyperactivated immune effector cells while supporting the regulatory immune machinery responsible for immune tolerance. For MG patients, this represents a nutritional strategy rationally aligned with the disease mechanism.
The Gundry Lectin-Reduction Model
Dr. Steven Gundry's work, particularly as articulated in The Plant Paradox, identifies dietary lectins — plant proteins found in grains, legumes, nightshade vegetables, and certain other plant foods — as a primary driver of intestinal permeability, systemic inflammation, and autoimmune pathogenesis. Lectins bind to the gut lining and disrupt tight junction integrity, creating the "leaky gut" phenomenon through which food-derived antigens and bacterial lipopolysaccharides (LPS) enter systemic circulation, chronically stimulating the immune system and sustaining the inflammatory environment in which autoimmune activity flourishes.[20]
For MG specifically, the lectin-reduction argument aligns with the emerging understanding of gut microbiome involvement in MG pathogenesis. Removing high-lectin foods reduces intestinal permeability, lowers systemic LPS burden, and reduces the chronic antigenic stimulation that maintains autoimmune activity. Combined with the Seyfried metabolic framework, the combined dietary approach supports both the metabolic and gut-barrier dimensions of the underlying immune dysregulation.